Local failure after primary radiotherapy in lung cancer: Is there a role for SBRT? by Amendola, Beatriz E. et al.
reports of practical oncology and radiotherapy 2 0 ( 2 0 1 5 ) 440–445
Available  online  at  www.sciencedirect.com
ScienceDirect
jo ur nal home p ag e: ht tp : / /www.e lsev ier .com/ locate / rpor
Original research article
Local  failure  after  primary  radiotherapy  in lung
cancer: Is there  a role  for SBRT?
Beatriz E. Amendola ∗, Marco A. Amendola, Naipy Perez, Xiaodong Wu,
Jesús  Blanco Suarez
Innovative Cancer Institute of South Florida, 6141 Sunset Drive, Suite 102, South Miami, FL 33143, United States
a  r  t  i  c  l  e  i  n  f  o
Article history:
Received 7 January 2015
Received in revised form 6 July 2015
Accepted 28 August 2015







a  b  s  t  r  a  c  t
Aim: Our purpose is to construe the role of stereotactic body radiation therapy (SBRT) in the
management of lung cancer from our early experience with SBRT for salvage treatment in
patients with recurrent lung cancer after initial radiation therapy.
Background: Locoregional recurrences are a frequent challenge in patients treated with radio-
chemotherapy for locally advanced NSCLC. Conventional external beam radiation therapy
(EBRT) is rarely given as salvage treatment because of the risk of toxicity. There is a paucity
of  published studies evaluating the role of SBRT in this clinical setting.
Materials and methods: Between 2008 and present, 10 patients with biopsy proven non-small
cell  lung cancer (NSCLC) underwent 14 radiosurgical procedures for salvage therapy after
failing initial radiation treatment. Patients’ age ranged from 54 to 88 years with a median
of  74 years in 6 males and 4 females. Intervals from initial radiation treatment to salvage
SBRT were 3–33 months with a median of 13 months. SBRT treatments were delivered using
Intensity Modulated Volumetric Arc Therapy (VMAT). All patients received concomitant
chemotherapy.
Results: Overall survival after salvage radiosurgery ranged from 6 to 41 months (mean
20  months, median 18 months). Four of the ten patients are alive with disease locally
controlled. Of the remaining 6 patients, 4 had distant progression of disease with brain
metastases and one had both brain and lung metastases. The other patient had a regional
failure. Toxicities were found in three of the ten (30%) patients with grade I pneumonitis.
Conclusion: In our early experience, salvage SBRT is an effective modality of treating patientswho failed after conventional irradiation, achieving excellent results in terms of local con-
trol  with acceptable toxicity. Further prospective studies are needed to determine optimal
fractionation schemes.
© 2015 Greater Poland Cancer Centre. Published by Elsevier Sp. z o.o. All rights reserved.∗ Corresponding author. Tel.: +1 305 298 0820.
E-mail address: bamendola@innovativecancer.com (B.E. Amendola)
http://dx.doi.org/10.1016/j.rpor.2015.08.001
1507-1367/© 2015 Greater Poland Cancer Centre. Published by Elsevier .
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.  Background
isease recurrence is the dominant cause of death after initial
reatment for lung cancer regardless of histology (NSCLC vs.
mall cell cancer), stage or initial treatment modality (surgery,
T, chemotherapy or combinations thereof).1 Patterns of fail-
re can be local (lung parenchyma, bronchial stump, chest
all), regional (mediastinal lymph nodes) or distant (brain,
iver and bone). Locoregional recurrences are reported in up
o 85% of the patients after radiochemotherapy for locally
dvanced NSCLC.2,3
The use of SBRT to treat early stage inoperable lung cancer
s now accepted as standard of care as per NCCN guidelines.4
here are relatively few studies evaluating the role of SBRT
n patients with recurrent lung cancer.5,6 Technical advances
ith better imaging including PET CT, with the ability to tar-
et not only large but also small tumor volumes, and with
mproved techniques of delivering highly focused and precise
adiation may have the potential to give these patients the
pportunity of long term remissions and even cures.6 Until
ecently, it was generally assumed that once definitive EBRT
ad been given, further RT could not be used since it would
ikely exceed normal tissue tolerances or at most it could
nly be used for palliation since it was expected that patients
ould not survive long enough to experience potential late
ffects.1 A few previous reports have suggested that palliative
nd definitive re-irradiation following fractionated radiothe-
apy for lung cancer is feasible.7,8 However, the possibility of
evere adverse events from re-irradiation with SBRT of the
ame site is still not well known. Larger clinical target vol-
mes and central tumor location have been associated with
ore severe toxicity.9,10
.  Materials  and  methods
e  used an Institutional Review Board (IRB) approved lung
BRT registry to identify all patients who received SBRT
or local failure after primary radiotherapy of lung cancer.
etween October 2008 and July 2014, 10 patients were treated
ith salvage thoracic SBRT for recurrent NSCLC after failed
onventional radiation (8 patients) or radiosurgery (2 patients).
here were 6 males and 4 females, ranging from 54 to 88 years
f age with a mean of 71 years and a median of 74 years. Inter-
als from initial radiation treatment to salvage SBRT ranged
rom 3 to 33 months with a mean of 13 months. Follow-up after
BRT salvage ranged from 6 to 41 months (mean 20 months,
edian 18 months). Recurrence was determined clinically by
DG-PET CT or by pathologic diagnosis. RECIST 1.1 was used
o evaluate response. Patients were considered to be medically
noperable by a multidisciplinary team. Guidelines for inoper-
bility included abnormal FEV1 of <30%, severely decreased
iffusion capacity of <40%, and predicted severe cardiac dis-
ase among other significant comorbidities. All patients had
 Karnofsky performance status >70%. All patients received
oncomitant chemotherapy.
All patients were simulated using CT with IV contrast.
atients were immobilized using a “frameless” semi-rigid
vacuated bag system or a body AquaplastTM. Abdominaltherapy 2 0 ( 2 0 1 5 ) 440–445 441
compression was used to decrease the tumor movement  due
to respiration. The internal tumor volume (ITV) was identified
using CT images obtained from three respiratory phases: nor-
mal, inspiration and expiration. The clinical target volume was
identical to the ITV. The planning target volume (PTV) was cre-
ated by expanding the ITV 3 mm in all directions to account
for patient movement  and setup uncertainty. Normal tissue
dose constraints were used as recommended by the Ameri-
can Association of Physicists in Medicine (AAPM) Task Group
TG 101.11
Treatments were delivered using a commercially available
linear accelerator with Volumetric Modulated Arc Therapy
(VMAT) with either single or multiple arcs of 6 MV photon
beams. Daily cone beam CT (CBCT) was obtained for treatment
alignment.
Dose prescription ranged from 6 Gy/fx to 20 Gy/fx deliv-
ered in three to five fractions, depending on the location of
the tumor: central versus peripheral, previous radiation dose
received and size of the lesion. The peripheral lung lesions far
from any other structure were treated using SBRT with 60 Gy
in 3 fractions of 20 Gy each, every other day. Those periph-
eral lesions close to the ribs were treated with 30–45 Gy in 3
fractions. Centrally located lesions received from 18 to 40 Gy
in fractions of 6–10 Gy (Figs. 1 and 2). The biological effective
dose (BED, with / = 10 Gy) ranged from 28.8 Gy to 180 Gy and
the total equivalent dose in 2 Gy/fx (EQD2) was 24–150 Gy.
There were 10 patients with 14 tumors treated: 9 central
and 5 peripheral in location.
Tumor volumes ranged from 2.9 cc to 101.1 cc (median
34.5 cc). Integrated boost was used in three patients to deliver
higher dose in the center of the lesions due to the large tumor
volume and/or critical location of the tumor.
We  followed the patients after salvage SBRT with CT of
the chest at one month and whole body PET-CT at 3 months
and then at 6-months intervals, unless there was an earlier
indication of recurrence from clinical exam or other imaging
studies.
All patients received concomitant platinum-based
chemotherapy as directed by the medical oncology team
using standard protocols. Our rationale to use SBRT for
salvage was originally intended as a palliative measure.
Eight patients had an in-field recurrence (IFR). Six patients
had regional failure (RF). Five patients had both IRF and RF.
Toxicity was assessed using the Common Terminology for
Adverse Events v3.0 (CTCAEv3).12
3.  Results
Overall follow-up/survival after salvage radiosurgery ranged
from 6 to 41 months (mean 20 months, median 18 months).
Four of the ten patients are alive with disease locally con-
trolled. Of the remaining 6 patients, 4 had distant progression
of disease with brain metastases and one had both brain and
lung metastases. The other patient had a regional failure.
None developed local failure. Using RECIST 1.1 to evaluate
response in the CT scans, there were 6 complete responses,
4 partial responses and in the remaining 4 there was stable dis-
ease after treatment. Toxicity was found in three of 10 (30%)
patients with grade I pneumonitis, one of them during the
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Fig. 1 – (A) Representative planning images of 74-year-old male with stage III lung cancer for initial course of conventional
fractionated RT in October 2008. (B) SBRT plan for salvage of in-field recurrence in the same patient in September 2011. Dose
delivered was 3 fractions of 10 Gy each to the ITV. At 41 months follow-up after SBRT retreatment the patient is alive with no
evidence of disease.
treatment and two more  than six months after salvage SBRT.
There was no evidence of any significant esophageal toxicity.
Of the four patients who are still alive, one has 41 months sur-
vival after salvage treatment and more  than 6 years after the
first radiation treatment course for his stage III lung cancer.
Patient characteristics are shown in Table 1, including previous
conventional radiation doses, toxicity and survival.
One patient treated elsewhere for a large mediastinal mass
causing superior vena cava syndrome who failed systemic
chemotherapy initially received conventional radiotherapy for
progression of disease. We  first re-treated the patient with
IMRT to the mediastinum for the voluminous tumor to max-
imum tolerance in that particular area (Fig. 3A). A 3-month
follow-up PET CT demonstrated 2 central areas of active dis-
ease prompting retreatment with SBRT to the 2 areas in
question (Fig. 3B and C). The patient eventually died 8 months
later from distant failure with local control in the thorax.
4.  DiscussionMultiple studies have demonstrated excellent tumor control
and limited toxicity with the use of SBRT. For patients with
T1 and T2 tumors with a high operative risk, SBRT results
in tumor control and overall survival comparable to reportedresults from surgery, with local control rates greater than
90%.13 Despite the effectiveness of EBRT and the success of
SBRT as a primary treatment modality for early-stage NSCLC,
there is a subset of patients who develop intrathoracic recurr-
ences after radiation treatment without evidence of distant
metastatic disease. Our rationale to use SBRT for salvage for
recurrent lung cancer was originally intended as a palliative
measure. However, over the years we  have seen results more
encouraging than merely palliation. An effective salvage ther-
apy for this group of patients is typically limited. The use of
radiation in general has not been the common approach in
patients with recurrent lung cancer. However, hypofraction-
ated techniques combined with systemic treatment have been
shown to be beneficial for those patients. Cetingoz et al. in 2008
reported the results of re-irradiation in 38 patients treated
with various regimens of hypofractionated XRT and found
symptomatic improvement and survival prolongation.14 They
emphasized the need of protecting normal structures to avoid
toxicity. In univariate analysis only the interval between two
courses was statically significant. Age, location of the recur-
rence or size of the tumor were not significant in terms of
overall survival.
Trovo et al. examined their experience using SBRT in a
recent retrospective study assessing toxicity and outcomes
of re-irradiation in patients previously treated with radical
reports of practical oncology and radiotherapy 2 0 ( 2 0 1 5 ) 440–445 443
Fig. 2 – (A) Initial fractionated RT to the lung primary lung cancer (July 2012) in an 88-year-old female with stage IV lung











0 Gy in 4 fractions of 10 Gy each. The patient died from mul
adiation therapy (50–60 Gy). They demonstrated in a small
umber of patients treated with 30 Gy in 5–6 fractions that
15xcellent local control could be obtained. They did, how-
ver, report a high rate of toxicity and recommended to initiate
 prospective study to determine the impact of this novel
pproach. Another recent paper from Karolinska Institute
ig. 3 – This is a 59-year-old female originally treated elsewhere 
etreatment of the voluminous tumor in the mediastinum using
B) and mediastinal (C) disease after 3 months using 3 fractions o brain metastases with local control in August 2014.
reported an increased incidence of Grades 3–5 toxicity in their
retrospective review of 29 patients reirradiated with SBRT on
1032 lung lesions (11 central, 21 peripheral). They concluded
that re-irradiation with SBRT is feasible with a warning of an
increased risk of toxicity when irradiating centrally located
lung tumors. This is consistent with the previous warning by
for superior vena cava syndrome using conventional RT. (A)
 EBRT with 45 Gy. (B and C) Salvage radiosurgery for hilar
f 5 Gy each with 7 Gy in the center respectively.
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Timmerman et al. regarding treatment of central tumors with
SBRT in a phase II study for medically inoperable early stage
lung cancer.16 Upon close examination, it was noted that their
dose was prescribed to about 67% isodose line at the periphery
of the PTV resulting in a maximal tumor dose of up to 150%
of the prescribed dose. One might speculate if this could be
the reason for the high toxicity. In our approach, isodose line
was typically around 90% and in our limited experience of 10
cases, we did not encounter such toxicity. Although we  have
asserted equal effort in minimizing damage to the surround-
ing normal tissues, dose to the surrounding lung tissue might
need to be considered from a different perspective, as most
of these lung tissues had already been dysfunctional due to
initial irradiation.
Reyngold et al. reported a retrospective study of 39 patients
with prior intra-thoracic conventionally fractionated radia-
tion therapy for a primary, recurrent or metastatic lung tumor
treated with salvage SBRT.9 Consistent with other recently
published single institution series, they showed high rates of
local control achieved by using SBRT.17–21 Their local control
rate of 64% at 2 years was lower than the one from Kelly et al.
with a 2-year in-field local control of 92%.17 Reyngold et al.
speculate that this could be related to the selection of fraction-
ation schemes with lower BED for patients with direct overlap
between the high-dose regions of SBRT and the prior con-
ventionally fractionated fields.9 Their local progression-free
rate at 1 and 2 years of 77% and 64%, respectively, compare
favorably with historical results of conventionally fraction-
ated re-irradiation: 51% and 42%, respectively, reported by Wu
et al.8; or 1-year results of SBRT experience reported by Trakul
et al. of 65.5%.18 Another study by Celada et al. of 13 patients
treated with SBRT, two of them previously irradiated, con-
cluded that SBRT seems to be a safe and effective option for
medically inoperable lung cancer patients.19
Factors that would predict a favorable outcome in the set-
ting of re-irradiation are largely unknown. Most data available
in the recently published literature comes from small sin-
gle institution studies. Overall survival, although improved, is
limited by systemic progression which probably depends par-
ticularly on patient selection.22 Distant failures are common
which suggest a role for concurrent or sequential chemother-
apy as suggested by Kilburn et al.23 Our experience in the
present series is too limited to make any specific recommen-
dation in this aspect. Prospective studies are essential for
standardization of the promising concept of using SBRT in the
re-irradiation of recurrent lung cancer.
In our series, survival after initial radiation therapy for
advanced lung cancer ranged from 9 to 74 months with a
median of 31 and an average of 35 months. A closed image-
based follow-up and the use of SBRT for salvage treatment
may explain these encouraging results.
Based on this initial experience, we would propose the use
of a regimen of salvage radiosurgery based on the location
of the lesion: central versus peripheral, tolerance of adja-
cent critical structures, volume of the tumor and previous
radiation dose. Consideration should be given to the use of
an integrated boost to deliver a higher dose to the center
of the tumor avoiding toxicity to surrounding normal tissue.













































reports of practical oncology and 
.  Conclusion
BRT offers a new opportunity and hope for patients with
ecurrent lung cancer after failing definitive radiation ther-
py. This is due to its ability to deliver highly focused radiation
ith minimized exposure to the surrounding normal tissues.
 brief review of the results of recently published clinical series
ttest to the virtues of SBRT in improving local control and
rolonging survival in patients that otherwise will rapidly suc-
umb to the disease. In our small series, patients tolerated
he treatment well despite concomitant chemotherapy and
he rate of remissions achieved with relatively minor toxic-
ty was encouraging. Consistent with the clinical outcomes
eported in the recent literature, our experience leads us to
onstrue that the role of SBRT for recurrent non-small cell lung
ancer after failing primary radiation treatment is helpful,
specially in achieving improved local disease control. Fur-
her investigation will be necessary to determine optimal dose
ractionation schemas and recommendations to decrease
oxicity.
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